Attenuation of islet-specific T cell responses is associated with C-peptide improvement in autoimmune type 2 diabetes patients

Clinical and Experimental Immunology

Volumn 171, Issue 2, 2013, Pages 164-170

  Brooks Worrell, B M ^a,b   Palmer, J P ^a,b  

^a VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Autoimmunity; PPAR ; Rosiglitazone; T cells; Type 2 diabetes

Indexed keywords

C PEPTIDE; GAMMA INTERFERON; GLIBENCLAMIDE; GLUCAGON; INTERLEUKIN 12; ROSIGLITAZONE; TETANUS TOXOID;

ADULT; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIABETIC PATIENT; DRUG EFFECT; FEMALE; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET CELL; PANCREAS ISLET CELL FUNCTION; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR DOWN REGULATION; T LYMPHOCYTE;

ADULT; AGED; AUTOANTIBODIES; AUTOIMMUNITY; C-PEPTIDE; CELLS, CULTURED; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GLYBURIDE; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOSUPPRESSION; INTERFERON-GAMMA; INTERLEUKIN-12; ISLETS OF LANGERHANS; MALE; MIDDLE AGED; PPAR GAMMA; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTES; THIAZOLIDINEDIONES;

EID: 84872166396     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12012     Document Type: Article

References (45)

1. Cunard R, Ricote M, DiCampli D etal. Regulation of cytokine expression by ligands of peroxisome proliferator activated receptors. J Immunol 2002; 1689:2795-2802.
2. Clark RB, Bishop-Bailey D, Estrada-Hernandez T, Hla T, Puddington L, Padula SJ. The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses. J Immunol 2000; 164:1364-1371.
3. Faveeuw C, Fougeray S, Angeli V etal. Peroxisome proliferator-activated receptor gamma activators inhibit interleukin-12 production in murine dendritic cells. FEBS Lett 2000; 486:261-266.
4. Harris SG, Phipps RP. The nuclear receptor PPAR gamma is expressed by mouse T lymphocytes and PPAR gamma agonists induce apoptosis. Eur J Immunol 2001; 31:1098-1105.
5. Housley WJ, O'Conor CA, Nichols F etal. PPAR gamma regulates retinoic acid-mediated DC induction of Tregs. J Leukoc Biol 2009; 86:293-301.
6. Chung SW, Kang BY, Kim TS. Inhibition of interleukin-4 production in CD4+ T cells by peroxisome proliferator-activated receptor gamma (PPAR-gamma) ligands: involvement of physical association between PPAR-gamma and the nuclear factor of activated T cells transcription factor. Mol Pharmacol 2003; 64:1169-1179.
7. Yang XY, Wang LH, Chen T etal. Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT. J Biol Chem 2000; 275:4541-4544.
8. Lei J, Hasegawa H, Matsumoto T, Yasukawa M. Peroxisome proliferator-activated receptor α and γ agonists together with TGFβ convert human CD4+CD25- T cells into functional Foxp3+ regulatory T cells. J Immunol 2010; 185:7186-7198.
9. Wohlfert EA, Nichols FC, Nevius E, Clark RB. Peroxisome proliferator-activated receptor gamma (PPARgamma) and immunoregulation: enhancement of regulatory T cells through PPARgamma-dependent and independent mechanisms. J Immunol 2007; 178:4129-4135.
10. Hontecillas R, Bassaganya-Riera J. Peroxisome proliferator activated receptor gamma is required for regulatory CD4+ T cell-mediated protection against colitis. J Immunol 2007; 178:2940-2949.
11. Cipolletta D, Feuerer M, Am L etal. PPAR-γ is a major driver of the accumulation and phenotype of adipose tissue Treg cells. Nature 2012; 486:549-553.
12. Bassaganya-Riera J, Reynolds K, Martino-Catt S etal. Activation of PPAR gamma and delta by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease. Gasteroenterology 2004; 127:777-791.
13. Beales PE, Liddi R, Giorgini AE etal. Troglitazone prevents insulin dependent diabetes in the non-obese diabetic mouse. Eur J Pharmacol 1998; 357:221-225.
14. 2 ameliorates experimental autoimmune encephalomyelitis. J Immunol 2002; 168:2508-2515.
15. Feinstein DL, Galea E, Gavrilyuk V etal. Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis. Ann Neurol 2002; 51:694-702.
16. Mueller C, Weaver V, Vanden Heuvel JP, August A, Cantorna MT. Peroxisome proliferator-activated receptor gamma ligands attenuate immunological symptoms of experimental allergic asthma. Arch Biochem Biophys 2003; 418:186-196.
17. Woerly G, Honda K, Loyens M etal. Peroxisome proliferator-activated receptors alpha and gamma down-regulate allergic inflammation and eosinophil activation. J Exp Med 2003; 198:411-421.
18. Nino M, Iwabuchi K, Kikuchi S etal. Amelioration of experimental autoimmune encephalomyelitis in C57BL/6 mice by an agonist of peroxisome proliferator-activated receptor γ. J Neuroimmunol 2001; 116:40-48.
19. Natarajan C, Bright JJ. Peroxisome proliferator-activated receptor-γ agonists inhibit experimental allergic encephalomyelitis by blocking IL-12 production, IL-12 signaling and Th1 differentiation. Genes Immun 2002; 3:59-70.
20. Dubuquoy L, Rousseaux C, Thuru X etal. PPARgamma as a new therapeutic target in inflammatory bowel diseases. Gut 2006; 55:1341-1349.
21. Pershadsingh HA. Peroxisome proliferator-activated receptor-gamma: therapeutic target for diseases beyond diabetes: quo vadis? Exp Opin Investig Drugs 2004; 13:215-228.
22. Drew PD, Xu J, Racke MK. PPAR-gamma: therapeutic potential for multiple sclerosis. PPAR Res 2008; 2008:627463-627472.
23. Schmidt S, Moric E, Schmidt M, Sastre M, Feinstein DL, Heneka MT. Anti-inflammatory and anti-proliferative actions of PPAR-gamma agonists on T lymphocyte derived from MS patients. J Leukoc Biol 2004; 75:478-485.
24. Ehses JA, Ellingsgaard H, Boni-Schnetzler M, Donath MY. Pancreatic islet inflammation in type 2 diabetes: from α and β cell compensation to dysfunction. Arch Physiol Biochem 2009; 115:240-247.
25. Donath MY, Schumann DM, Faulenbach M, Ellingsgaard H, Perren A, Ehses JA. Islet inflammation in type 2 diabetes. Diabetes Care 2008; 31:S161-164.
26. Richardson SJ, Wilcox A, Bone AJ, Foulis AK, Morgan NG. Islet-associated macrophages in type 2 diabetes. Diabetologia 2009; 52:1686-1688.
27. Brooks-Worrell B, Palmer JP. Immunology in the clinic review series; focus on metabolic diseases: development of islet autoimmune disease in type 2 diabetes patients: potential sequelae of chronic inflammation. Clin Exp Immunol 2012; 167:40-46.
28. Brooks-Worrell B, Narla R, Palmer JP. Biomarkers and immune-modulating therapies for Type 2 diabetes. Trends Immunol 2012; 33:546-553.
29. Brooks-Worrell B, Juneja R, Minokadeh A, Greenbaum CJ, Palmer JP. Cellular immune response to human islet proteins in antibody-positive type 2 diabetic patients. Diabetes 1999; 48:983-988.
30. Mayer A, Fabien N, Gutowski MC etal. Contrasting cellular and humoral autoimmunity associated with latent autoimmune diabetes in adults. Eur J Endocrin 2007; 157:53-61.
31. Brooks-Worrell B, Reichow JL, Goel A, Ismail H, Palmer JP. Identification of autoantibody negative autoimmune type 2 diabetes patients. Diabetes Care 2011; 34:168-173.
32. Goel A, Chiu H, Felton J, Palmer JP, Brooks-Worrell B. T cell responses to islet antigens improves detection of autoimmune diabetes and identifies patients with more severe β-cell lesions in phenotypic type 2 diabetes. Diabetes 2007; 56:2110-2115.
33. Miyaaki Y, DeFronzo RA. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients. Diabetes Obes Metab 2008; 10:1204-1211.
34. Kahn SE, Haffner SM, Heise MA etal. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355:2427-2443.
35. Brooks-Worrell B, Starkebaum GA, Greenbaum C, Palmer JP. Peripheral blood mononuclear cells of insulin-dependent diabetic patients respond to multiple islet cell proteins. J Immunol 1996; 157:5668-5674.
36. Brooks-Worrell B, Gersuk VH, Greenbaum C, Palmer JP. Intermolecular antigen spreading occurs during the pre-clinical period of human type 1 diabetes. J Immunol 2001; 166:5265-5270.
37. Seyfert-Margolis V, Gisler TD, Asare AL etal. Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled study. Diabetes 2006; 55:2588-2594.
38. Herold KC, Brooks-Worrell B, Palmer J etal. Validity and reproducibility of measurement of islet autoreactivity by T cell assays in subjects with early type 1 diabetes. Diabetes Care 2009; 58:2588-2595.
39. Brooks-Worrell B, Warsen A, Palmer JP. Improved T cell assay for identification of Type 1 diabetes patients. J Immunol Methods 2009; 344:79-83.
40. Xu J, Drew PD. Peroxisome proliferator-activated receptor-g agonists suppress the production of IL-12 family cytokines by activated glia. J Immunol 2007; 178:1904-1913.
41. Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, O'Garra A, Murphy KM. Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 1993; 260:547-549.
42. Manetti R, Parronchi P, Giudizi MG etal. Natural killer cell stimulatory factor (interleukin-12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4 producing Th cells. J Exp Med 1993; 177:1199-1204.
43. Windhagen A, Newcombe J, Dangond F etal. Expression of co-stimulatory molecules B7-1 (CD80), B-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J Exp Med 1995; 182:1985-1996.
44. Comabella M, Balashov K, Issaadeh S, Smith D, Weiner HL, Khoury SJ. Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy. J Clin Invest 1998; 102:671-678.
45. Nicoletti F, Patti F, Cocuzza C etal. Elevated serum levels of interleukin-12 in chronic progressive multiple sclerosis. J Neuroimmunol 1996; 70:87-90.